Dr. John Marshall on Individualizing Treatment for Patients With Colorectal Cancer

John Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, discusses the individualization of treatment of patients with colorectal cancer (CRC). Marshall says while maintaining VEGF-inhibition does promote a better overall survival advantage, there is not a major difference between many of the frontline therapies. He adds that the order in which medical professionals decide to use these treatments is entirely up to the individual and based on what the patient responds to.